This page uses content from Wikipedia and is licensed under CC BY-SA.

Indium (111In) capromab pendetide

Indium (111In) capromab pendetide
Monoclonal antibody
TypeWhole antibody
TargetGlutamate carboxypeptidase II
Clinical data
Trade namesProstascint
ATC code
CAS Number
  • none
 ☒N☑Y (what is this?)  (verify)

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]

Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]


  1. ^ a b Manyak, M. J. (2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–81. doi:10.1586/14737140.8.2.175. PMID 18279057.
  2. ^ WHO Drug Information
  3. ^ Kahn, Daniel; J. Christopher Austin; Robert T. Maguire; Sara J. Miller; Jack Gerstbrein; Richard D. Williams (1999). "A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99. doi:10.1089/cbr.1999.14.99.